NCT06482294View on ClinicalTrials.gov

CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

July 1, 2025

Conditions
Asthma
Interventions
DRUG

Salbutamol

One arm is a combination of salbutamol and fluticason as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).

DRUG

Fluticason either Beclometasone or Budesonide

One arm is a combination of salbutamol and an ICS as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).

Trial Locations (1)

44121

Research Centre on Asthma and COPD, University of Ferrara, Ferrara

All Listed Sponsors
lead

Università degli Studi di Ferrara

OTHER

NCT06482294 - CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma | Biotech Hunter | Biotech Hunter